<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630731</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1038</article-id><article-id pub-id-type="publisher-id">ofx163.1038</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grupping</surname><given-names>Katrijn</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Campora</surname><given-names>Laura</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Douha</surname><given-names>Martine</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Heineman</surname><given-names>Thomas C</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Klein</surname><given-names>Nicola P</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Lal</surname><given-names>Himal</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>James</given-names></name><degrees>MD, FAAFP</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Oostvogels</surname><given-names>Lidia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>GSK</institution>, <addr-line>Wavre</addr-line>, <country>Belgium</country></aff><aff id="AF0002">
<label>2</label>
<institution>Genocea Biosciences</institution>, <addr-line>Cambridge, MA</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Kaiser Permanente Vaccine Study Center</institution>, <addr-line>Oakland, California</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Pfizer Inc.</institution>, <addr-line>Collegeville, Pennsylvania</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Foothill Family Clinic</institution>, <addr-line>Salt Lake City, Utah</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 152. Herpes Zoster Vaccine</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S414</fpage><lpage>S414</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1038.pdf"></self-uri><abstract><title><offsets xml_i="4946" xml_f="4954" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="4982" xml_f="4992" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="5003" xml_f="5541" txt_i="31" txt_f="569">Herpes zoster (HZ), caused by reactivation of varicella-zoster virus (VZV), typically manifests as a dermatomal rash and can lead to postherpetic neuralgia (PHN). HZ and PHN risk increase with age. Efficacy against HZ induced by a live-attenuated zoster vaccine (ZVL; Merck) declines following vaccination (21% in years 5–12 post-vaccination). To ensure protection, revaccination can be considered. Therefore, we assessed immunogenicity and safety of HZ/su, a non-live candidate vaccine containing VZV glycoprotein E (gE) subunit and AS01</offsets><sub><offsets xml_i="5546" xml_f="5547" txt_i="569" txt_f="570">B</offsets></sub><offsets xml_i="5553" xml_f="5704" txt_i="570" txt_f="721"> adjuvant system (GSK), in adults previously vaccinated with ZVL ≥5 years before, (HZ-PreVac) compared with adults not vaccinated with ZVL (HZ-NonVac).</offsets></p></sec><sec id="s2"><title><offsets xml_i="5734" xml_f="5741" txt_i="723" txt_f="730">Methods</offsets></title><p><offsets xml_i="5752" xml_f="6559" txt_i="731" txt_f="1535">In this phase III, group-matched, open, multicenter study (NCT02581410), 2 parallel groups of adults ≥65 years of age (YOA) received 2 HZ/su doses 2 months apart. A co-primary objective was to compare humoral immune responses 1 month post-dose 2 (M3) in the 2 groups (non-inferiority criterion: upper limit [UL] of the 95% confidence interval [CI] for HZ-NonVac/HZ-PreVac adjusted anti-gE antibody geometric mean concentration [GMC] ratio &lt;1.5). Humoral and cellular immune responses were evaluated at various time points. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post each dose, respectively. Serious AEs (SAEs), HZ cases and potential immune-mediated diseases (pIMDs) will be recorded until study end. Here, we present data up to M3, as the study is still ongoing.</offsets></p></sec><sec id="s3"><title><offsets xml_i="6589" xml_f="6596" txt_i="1537" txt_f="1544">Results</offsets></title><p><offsets xml_i="6607" xml_f="7185" txt_i="1545" txt_f="2123">430 participants were vaccinated. M3 humoral immune responses in HZ-PreVac were non-inferior to those in HZ-NonVac and the co-primary objective was met as the UL of the 95% CI of the adjusted GMC ratio was 1.17 (Table 1). In addition, there were no apparent differences in CD4[2+] T-cell frequencies between groups (Figure 1). No clinically meaningful differences between frequencies of solicited AEs, unsolicited AEs or SAEs in the 2 groups were observed (Table 2). No SAEs considered vaccine-related by investigators, no suspected HZ cases and no pIMDs were reported up to M3.</offsets></p></sec><sec id="s4"><title><offsets xml_i="7215" xml_f="7225" txt_i="2125" txt_f="2135">Conclusion</offsets></title><p><offsets xml_i="7236" xml_f="7370" txt_i="2136" txt_f="2270">HZ/su vaccination in adults ≥65 YOA who previously received ZVL stimulates strong immune responses and does not raise safety concerns.</offsets></p></sec><sec id="s10"><title><offsets xml_i="7401" xml_f="7408" txt_i="2272" txt_f="2279">Funding</offsets></title><p><offsets xml_i="7419" xml_f="7449" txt_i="2280" txt_f="2310">GlaxoSmithKline Biologicals SA</offsets></p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0450"></graphic></fig><fig fig-type="figure" id="F2" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0451"></graphic></fig><fig fig-type="figure" id="F3" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0452"></graphic></fig></sec><sec id="s5"><title><offsets xml_i="7869" xml_f="7880" txt_i="2312" txt_f="2323">Disclosures</offsets></title><p><offsets xml_i="7891" xml_f="7892" txt_i="2324" txt_f="2325">
</offsets><bold><offsets xml_i="7898" xml_f="7909" txt_i="2325" txt_f="2336">K. Grupping</offsets></bold><offsets xml_i="7916" xml_f="7960" txt_i="2336" txt_f="2380">, GSK group of companies: Employee, Salary; </offsets><bold><offsets xml_i="7966" xml_f="7976" txt_i="2380" txt_f="2390">L. Campora</offsets></bold><offsets xml_i="7983" xml_f="8027" txt_i="2390" txt_f="2434">, GSK group of companies: Employee, Salary; </offsets><bold><offsets xml_i="8033" xml_f="8041" txt_i="2434" txt_f="2442">M. Douha</offsets></bold><offsets xml_i="8048" xml_f="8092" txt_i="2442" txt_f="2486">, GSK group of companies: Employee, Salary; </offsets><bold><offsets xml_i="8098" xml_f="8112" txt_i="2486" txt_f="2500">T. C. Heineman</offsets></bold><offsets xml_i="8119" xml_f="8189" txt_i="2500" txt_f="2570">, GSK group of companies: Consultant and Shareholder, Consulting fee; </offsets><bold><offsets xml_i="8195" xml_f="8206" txt_i="2570" txt_f="2581">N. P. Klein</offsets></bold><offsets xml_i="8213" xml_f="8492" txt_i="2581" txt_f="2856">, GSK group of companies: Investigator, Grant recipient sanofi pasteur: Investigator, Grant recipient; Merck &amp; Co: Investigator, Grant recipient; MedImmune: Investigator, Grant recipient; Protein Science: Investigator, Grant recipient; Pfizer: Investigator, Grant recipient; </offsets><bold><offsets xml_i="8498" xml_f="8504" txt_i="2856" txt_f="2862">H. Lal</offsets></bold><offsets xml_i="8511" xml_f="8702" txt_i="2862" txt_f="3053">, Pfizer: Employee and Shareholder, Salary and Stock as part of compensation; GSK group of companies: Employee at the time of study and Shareholder, Salary and Stock as part of compensation; </offsets><bold><offsets xml_i="8708" xml_f="8719" txt_i="3053" txt_f="3064">J. Peterson</offsets></bold><offsets xml_i="8726" xml_f="8795" txt_i="3064" txt_f="3133">, GSK group of companies: Investigator, Principal investigator fees; </offsets><bold><offsets xml_i="8801" xml_f="8814" txt_i="3133" txt_f="3146">L. Oostvogels</offsets></bold><offsets xml_i="8821" xml_f="8890" txt_i="3146" txt_f="3215">, GSK group of companies: Employee and Shareholder, Salary and Shares</offsets></p></sec></abstract><counts><page-count count="1"></page-count></counts></article-meta></front></article>